Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: Associations with stimulant treatment

Ambulatory Pediatrics

Volumn 6, Issue 1, 2006, Pages 45-53

  Leibson, Cynthia L ^a   Barbaresi, William J ^a   Ransom, Jeanine ^a   Colligan, Robert C ^a   Kemner, Jason ^b   Weaver, Amy L ^a   Katusic, Slavica K ^a  

^a Mayo Clinic   (United States)

^b McNeil Laboratories Inc   (United States)

Author keywords

Attention deficit hyperactivity disorder; Emergency department; Stimulant treatment

Indexed keywords

CENTRAL STIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITAL BILLING; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIGRATION; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 33644508348     PISSN: 15301567     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ambp.2005.08.005     Document Type: Article

References (38)

1. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention-deficit hyperactivity disorder (ADRHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21:195-206.
2. DeBar LL, Lynch FL, Boles M. Healthcare use by children with attention deficit/hyperactivity disorder with and without psychiatric comorbidities. J Behav Health Serv Res. 2004;31:312-323.
3. Miller AR, Brehaut JC, Raina P, et al. Use of medical services by methylphenidate-treated children in the general population. Ambul Pediatr. 2004;4:174-180.
4. Swensen AR, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health. 2004;35:346-347.
5. Burd L, Klug MG, Coumbe MJ, Kerbeshian J. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol. 2003;18:555-561.
6. Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/ hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatr. 2003;42:1415-1423.
7. Brehaut JC, Miller A, Raina P, McGrail KM. Childhood behavior disorders and injuries among children and youth: a population-based study. Pediatrics. 2003; 111:262-268.
8. Chan E, Zhan CL, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder - national estimates from the Medical Expenditure Panel survey. Arch Pediatr Adolesc Med. 2002; 156:504-511.
9. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:71-78.
10. Kelleher JK, Childs GE, Harmon JS. Healthcare costs for children with attention-deficit/hyperactivity disorder. Econ Neurosc. 2001;3:60-63.
11. Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/ hyperactivity disorder. JAMA. 2001;285:60-66.
12. Woodward LJ, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional difficulties in adolescence. J Am Acad Child Adolesc Psychiatr. 2000;39:627-634.
13. DiScala C, Lescohier I, Barthel M, Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics. 1998; 102:1415-1421.
14. Cox DJ, Humphrey JW, Merkel L, et al. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract. 2004;17:235-239.
15. Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J Nerv Ment Dis. 2001; 189:63-64.
16. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of AD/HD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr. 2001;22:60-73.
17. http://www.intelihealth.com/IH/ihtIH/WSIHW000/8271/8014/382756.html. Accessed May 17, 2004.
18. Leibson CL, Long KH. Economic implications of attention-deficit hyperactivity disorder for healthcare systems. Pharmacoeconomics. 2003;21:1239-62.
19. Katusic SK, Barbaresi WJ, Colligan RC, et al. Case definition in epidemiologic studies of AD/HD. Ann Epidemiol. 2005;15:430-437.
20. Barbaresi W, Katusic SK, Colligan RC, et al. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med. 2002; 156:217-224.
21. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. The impact of psychostimulant treatment on substance abuse among children with ADHD: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005; 15:764-776.
22. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274.
23. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trails: a population-based study. J Natl Cancer Inst. 1999;91:847-853.
24. http://www.apc-solutions.net/fedregs/000801fd.httn. Accessed March 20, 2005.
25. http://data.bls.gov/PDQ/outside.jsp?survey=cu. Accessed March 20, 2005.
26. Katusic SK, Colligan RC, Barbaresi WJ, et al. Potential influence of migration bias in birth cohort studies. Mayo Clin Proc. 1998;73:1053-1061.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
28. Melton LJ III. The threat to medical records research. N Engl J Med. 1997;337:1466-1470.
29. Drug Topics Red Book. Montvale, NJ: Medical Economics Co. Inc.; 2000.
30. Barbaresi WJ, Katusic SK, Colligan RC, et al. Co-morbidities among children with AD/HD: perspectives from a population-based study. Pediatr Res. 2004(April);55: 1A.
31. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
32. Noether GE. Sample size determination for some common nonparametric tests. JASA. 1987;82:645-647.
33. Wolraich ML, Hannah JN, Pinnock TY, et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a countywide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319-324.
34. Baumgartel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry. 1994;34:629-638.
35. Pelham WE, Gnagy EM, Greenslade KE, Milich R. Teacher ratings of DSM-III-R symptoms for the disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry. 1992;31:210-218.
36. Szatmari P, Offord DR, Boyle MH. Ontario Child Health Study. J Child Psychol Psychiatry. 1989;30:219-230.
37. Guevara J, Lozano P, Wickizer T, et al. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:733-739.
38. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective. Am J Child Adolesc Psychiatry. 2000;39:975-984.